Aim: To investigate whether human multiple myeloma (MM) cells secrete microvesicles (MVs) and whether the MVs secreted from MM cells (MM-MVs) promote angiogenesis. Methods: RPMI8226 human MM cells and EA.hy926 human umbilical vein cells were used. MVs isolated from RPMI 8226 cells were characterized under laser confocal microscopy, electron microscopy and with flow cytometry. The fusion of MM-MVs and EA.hy926 cells was studied under confocal microscopy, and the transfer of CD138 to EA.hy926 cells was demonstrated with flow cytometry. The proliferation, invasion and tube formation of EA.hy926 cells in vitro were evaluated using MTT, transwell migration and tube formation assays, respectively. The vasculization of EA.hy926 cells in vivo was studied using Matrigel plug assay. The expression of IL-6 and VEGF was analyzed with PCR and ELISA. Results: MM-MVs from the RPMI 8226 cells had the characteristic cup-shape with diameter of 100-1000 nm. Most of the MM-MVs expressed phosphatidylserine and the myeloma cell marker CD138, confirming that they were derived from myeloma cells. After added to EA.hy926 cells, the MM-MVs transferred CD138 to the endothelial cells and significantly stimulated the endothelial cells to proliferate, invade, secrete IL-6 and VEGF, two key angiogenic factors of myeloma, and form tubes in vitro and in vivo. Conclusion: Our results confirm the presence of MVs in MM cells and support the idea that MM-MVs are newfound mediators for myeloma angiogenesis and may serve as a therapeutic target to treat MM.
Introduction
The development of multiple myeloma (MM) is a complex, multistep process. Accumulating evidence has shown that the interaction and crosstalk of myeloma plasma cells with the surrounding host cells play key roles in disease progression [1] [2] [3] . Many findings suggested that MM cells possess angiogenic capabilities through the release of angiogenic cytokines, which leads to substantial bone marrow neovascularization [4, 5] . However, the proangiogenic properties of myeloma cells and the biological mechanisms of MM-induced angiogenesis have not yet been elucidated [5] . Microvesicles (MVs), also known as shedding vesicles or microparticles, are endosome-derived organelles that are spontaneously secreted from normal and neoplastic cells.
These vesicles were originally considered to be inert cellular debris [6] [7] [8] [9] [10] ; however, it is now known that both their cytoplasmic fraction and their membrane contain a variable spectrum of molecules, and this pattern specifically reflects the donor cell that secreted them [9, 11, 12] . MVs can reach the local target cells but can also travel over long dis tances [12, 13] . A large number of studies have reported that tumor cellderived MVs (TMVs) reflect the special potential of tumor cells for the expansion of the tumor, independently from cell to cell contact [14, 15] . Recently, a growing body of evidence suggests that TMVs contain a selective enrichment of a discrete set of cellular molecules that can be transferred into the target cells [16] [17] [18] [19] . Interestingly, Thompson et al [20] recently confirmed that exosomes, which are a different kind of vesicle with different origins, sizes and content, are secreted by myeloma cells, and emerging evidence has shown that TMVs act as novel angiogenic mediators and can stimulate angiogenesis in tumors [14, 19, [21] [22] [23] ; however, it is not clear whether MVs can be secreted by myeloma cells (MM-MVs).
In the present study, we investigated the presence and 
Materials and methods

Cell culture
The RPMI 8226 human myeloma cell line and the EA.hy926 human umbilical vein cell line were purchased from the American Type Culture Collection (ATCC, Rockville, MD, USA) and cultured in a humidity-controlled incubator (37 °C, 5% CO 2 ).
Isolation of MVs
MVs were isolated by differential ultracentrifugation [13] . Briefly, the RPMI 8226 cells (1×10 7 ) were washed twice with PBS and were then incubated in serum-free DMEM (20 mL) for 24 h. Then, the media were collected by centrifugation at 1000×g for 5 min. The supernatant was centrifuged at 4000×g for 1 h to remove the cellular debris, and the resulting supernatant was then distributed into EP tubes for an additional centrifugation at 16 000×g for 1 h. The supernatant was discarded to remove the exosomes, and the MV pellet was washed and resuspended in PBS, followed by another centrifugation at 16 000×g for 1 h to remove the remaining exosomes. The protein content of the MV preparation was quantified using the Bradford method (Bio-Rad, Hercules, CA, USA) as previously reported [24] . All of the centrifugations were performed at 4 °C, and the isolated MVs were stored in PBS at 4 °C until use.
Transmission electron microscopy (TEM) and fluorescence microscopy (FM) TEM was performed as previously reported [25] . For FM, the purified MM-MVs were stained using the PKH26 Red Fluorescent Cell Linker Kit (Sigma-Aldrich, St Louis, MO, USA) according to the kit's instructions, and the MM-MVs were observed by FM (Olympus, Tokyo, Japan).
Membrane interaction assay
As previously reported [13] , the MM-MVs were stained with PKH26 (1 μmol/L), and the EA.hy926 cells were incubated with the PKH26-stained MM-MVs for 2, 4, 6, 12, 18, or 24 h at 37 °C. The cells were then washed twice with PBS, counterstained with DAPI (Beyotime, Shanghai, China) and visualized using a confocal microscope (NikonA1Si, Nikon, Tokyo, Japan). Furthermore, to analyze the MM-MV markers, standard microbeads with a diameter of 1 μm (Sigma-Aldrich, St Louis, MO, USA) were used to set the upper size limit of the MVs, and this population was used to gate the MVs. MMMVs were stained with both annexin V and an anti-CD138 antibody and were analyzed by flow cytometry using a FACScan flow cytometer (Becton Dickinson, San Diego, CA, USA). The EA.hy926 cells were incubated with 5 μg/mL MM-MVs for 24 h, washed with PBS and then stained for CD138 to check the incorporation of the MM-MVs into the EA.hy926 cells by flow cytometry.
MTT analysis
Briefly, EA.hy926 cells (5×10 4 cells/mL) were seeded into each well of a 96-well microplate in a final volume of 200 μL and were cultured overnight at 37 °C in a humidified, 5% CO 2 atmosphere (v/v). Then, 10 μL of MM-MVs were added at a final concentration of 5 μg/mL and cultured for an additional 12, 24, 36, or 48 h. The MTT assay was performed in triplicate.
Transwell migration assay
The transwell (Corning Inc, NY, USA) migration assay was performed as previously reported [26] . The bottom chambers were filled with 600 μL of DMEM supplemented with 10% FBS, and the top chambers were seeded with 5×10 4 EA.hy926 cells/well in 100 μL of medium; 5 μg/mL MM-MVs or PBS (control) was added to the cells in the top chamber. After 12, 24, 36, or 48 h of migration, the invasive cells found in the bottom chamber were fixed and counted.
Tube formation assay Matrigel (growth factor reduced) was thawed at 4 °C, and each well of prechilled 96-well plates was coated with 50 μL Matrigel, then incubated at 37 °C for 1 h. EA.hy926 cells (2×10 3 ), in a volume of 100 μL of DMEM supplemented with 0.5% FBS, were added to each well, along with 10 μL of MM-MVs (at a final concentration of 5 μg/mL) or PBS. After 3, 6, 9, or 12 h of incubation at 37 °C with 5% CO 2 , the endothelial cell tubular structure formation was quantified by calculating the tube length under a high-powered field (HPF; 200×) with an Olympus inverted microscope, and the inhibition percentage was calculated by setting the untreated wells to 100% [26] .
Matrigel plug assay
All animal experiments were conducted at Tongji Medical College of Huazhong University with Hubei Legislation for Animal Care. Briefly, 6-week-old C57/BL6 mice (n=3 each group) were injected subcutaneously in the midventral abdominal region with 500 μL of Matrigel containing 50 μg/plug MMMVs or PBS as a control. After 6 d, the mice were sacrificed, the plugs were removed, and analysis was performed as previously described [26] .
Conventional PCR and ELISA assay EA.hy926 cells (5×10 4 cells/ml) were treated with MM-MVs as in the Transwell migration assay. The following primer sequences were used: VEGF, sense 5′-CTGCTGTCTTGGGTG-CATTG-3′ and antisense 5′-TTCACATTTGTTGTGCTGTAG-3′ (378 bp); IL-6, sense 5′-CCTTAAAGCTGCGCAGAATG-3′ and antisense 5′-ATTCAATGAGGAGACTTGCC-3′ (284 bp). ELISA Kits (Boster, Wuhan, China) were used to analyze the VEGF and IL-6 present in the supernatants. 
Statistical analysis
The data are expressed as the mean±SEM of at least three experiments. Statistical analyses were performed using a paired Student's t test, and the differences were considered statistically significant when P<0.05.
Results
Validation of RPMI8226 cell-derived microvesicles
The presence of RPMI 8226 cell-derived MM-MVs was validated using TEM, FM and flow cytometry to examine the morphological and immunophenotyping characteristics. As shown in Figure 1A , a representative TEM shows the characteristic cup-shaped morphology of the MM-MVs, and the scale bar shows that these MM-MVs have a diameter range of 100-1000 nm. Exposure of phosphatidylserine (PS) and CD138 are typical markers for MVs [27] and myeloma cells [28] , respectively. We used Annexin-V and an anti-CD138 antibody to mark the MVs that were released from the myeloma cells. Most of the MM-MVs from the RPMI 8226 cells expressed PS (94.5%±3.6%) and CD138 (82.1%± 5.3%) ( Figure 1B ), confirming that these vesicles were derived from myeloma cells. Exosomes are stored as intraluminal vesicles within multivesicular bodies in the late-endosome; as such, they share biochemical characteristics with the internal vesicles of multivesicle bodies. The vesicles isolated from the RPMI 8226 cells mostly expressed PS and CD138 with a size of 100 to 1000 nm and were, therefore, considered MVs, not exosomes.
MM-MVs integrate into EA.hy926 cells
MVs can be internalized by the target cells as previously reported [29] , and we posited that MM-MVs from RPMI 8226 cells could analogously interact with endothelial cells. After incubation with EA.hy926 cells for various times, fluorescent microscopy analysis confirmed that the MM-MVs were incorporated into the EA.hy926 cells, and a time-dependent transfer of the fluorescent MM-MVs (labeled with PKH-26) was observed (Figure 2A-2F) . After 24 h at 37 °C, most of the MMMVs fluorescence was located around the DAPI-stained nuclei of the EA.hy926 cells, suggesting an almost complete transfer from the MM-MVs to the target cells. Because EA.hy926 cells do not express the CD138 surface marker, we further investigated CD138 expression on EA.hy926 cells to verify the interaction of the MM-MVs with the EA.hy926 cells. As shown in Figure 2G , after incubation for 24 h, 3% of the EA.hy926 cells expressed CD138. This successful transfer of CD138 from the MM-MVs to the endothelial cells also confirmed the interaction between these bodies.
MM-MVs promote the proliferation of EA.hy926 cells Proliferation of endothelial cells is one step in the multi-step process of angiogenesis. To investigate the effect of MM-MVs on this key step, the MM-MVs were incubated with EA.hy926 cells for various amounts of time, and the proliferation of the EA.hy926 cells was assessed using an MTT test. As shown in Figure 3 , MM-MVs significantly induced the proliferation of the EA.hy926 in a time-dependent manner, and the proliferative effect was significant after 24 h of incubation. Notably, after 48 h, the EA.hy926 cells co-cultured with MMMVs continued to proliferate, whereas the proliferation of the cells cultured without MM-MVs began to decrease. This 
MM-MVs induce the invasion of EA.hy926 cells
Cell migration and invasion are critical for endothelial cells to form blood vessels during tumor angiogenesis; therefore, these processes are necessary for tumor growth and metastasis. We further investigated the effects of MM-MVs on the chemotactic motility of EA.hy926 cells, which was determined using the transwell cell invasion assay. As shown in Figure 4 , after incubation with 5 μg/mL MM-MVs for 12, 24, or 36 h, the number of hexamethyl pararosaniline-stained EA.hy926 cells on the bottom of the membrane was significantly increased compared to the PBS control. This indicated that MM-MVs could significantly promote the invasion of EA.hy926 cells ( Figure  4A and 4B). However, this effect was not observed after 48 h incubation with MM-MVs; this indicated that the ability of the MM-MVs to promote invasion of endothelial cells had reached its peak.
MM-MVs induce capillary structure formation in EA.hy926 cells in vitro and vascularization in vivo
Tube formation of endothelial cells is another key step in the were not statistically significant, compared to the PBS control group, after 3 or 6 h of incubation. However, after 9 h of incubation, the MM-MVs significantly promoted tube formation of the endothelial cells in a time-dependent manner ( Figure 5A , 5B).
To further confirm the effects of MM-MVs on the vascularization of EA.hy926 cells in vivo, the mouse Matrigel plug assay was performed in the presence or absence of 5 μg/mL MM-MVs using six-week-old C57/BL6 mice. The Matrigel plugs were removed after 6 days. As shown in Figure 5C , the plugs containing the MM-MVs were dark red after fixation, and the vessels were abundantly filled with intact red blood cells. In contrast, the plugs containing only PBS were significantly paler, indicating less vessel formation in vivo. After H&E staining, the number of neovessels were analyzed and quantified ( Figure 5D ). The results indicated that 5 μg/mL MM-MVs could significantly induce the vascularization of EA.hy926 cells in vivo.
MM-MVs promote autocrine IL-6 and VEGF production in EA.hy926 cells The angiogenic switch in MM is driven by various angiogenic cytokines, which are secreted in the bone marrow microenvironment. IL-6 and VEGF, the two important cytokines, are critically important for myeloma cell proliferation, angiogenesis and disease progression [30, 31] . In a paracrine loop, To determine the effects of MM-MVs on IL-6 and VEGF secretion on endothelial cells, we analyzed the levels of these proteins in EA.hy926 cells or in the conditioned medium. After incubation with or without MM-MVs for 12, 24, 36, or 48 h, we examined the levels of IL-6 and VEGF mRNA in the EA.hy926 cells, and the results demonstrated that both IL-6 and VEGF mRNA levels were higher in the MMMVs-treated EA.hy926 cells than in the PBS group, as shown in Figure 6A . Moreover, the ELISA results indicated that the levels of IL-6 and VEGF in the medium from EA.hy926 cells were significantly higher in the MM-MVs-treated EA.hy926 cells compared to the PBS group ( Figure 6B and 6C) . Taken together, these results indicated that MM-MVs could promote IL-6 and VEGF expression and secretion in EA.hy926 cells.
Discussion
It is known that cells communicate and exchange information by employing classical mechanisms, such as secreting soluble factors or cell-to-cell adhesion contacts [32] . Although these classical events have been commonly thought of as the predominant modes of cell-to-cell communication, a novel type of vesicle secretion has recently received a great deal of attention [8, 9, 15, 33] . Though the secretion of exosomes by myeloma [21, 34] , there have been no previous studies about MM-MVs. The current study identified MM-MVs as a potential mediator of angiogenesis.
Vesicles are usually classified into two different types, exosomes and MVs, which are also called shedding vesicles, shedding microvesicles, or microparticles [6] . Irrespectively of their origin, MVs are circular membrane fragments that retain the characteristics of the parental cell. In contrast, exosomes are smaller and more homogenous; these vesicles originate in the endosome and range from 30 to 120 nm in size [35, 36] . In this study, isolated TMVs from RPMI 8226 cells had a large size distribution that was distinct from the exosomes of myeloma cells [20] . Furthermore, these MM-MVs expressed the membrane components PS and CD138. These data demonstrated that the vesicles were not exosomes but were instead MVs from the MM cells.
It has been reported that microparticle-mediated transfer of viral receptors confers new functions to the target cells [37] . The current study confirmed the transferred expression of syndecan-1 to the endothelial cells. MM is characterized by high expression of syndecan-1 (CD138), which is present on the surface of myeloma cells and can be shed into the tumor microenvironment [4, [38] [39] [40] . Recently, exosome secretion by myeloma cells and the protein cargo of sydecan-1 were reported to dramatically increase when myeloma cells were exposed to exogenous heparanase or when the expression of heparanase was enhanced [20] . Furthermore, we showed that MM-MV-treated endothelial cells had enhanced levels of VEGF and IL-6, the key growth factors involved in myeloma [41] . These results support the role of MM-MVs in angiogenesis, consistent with findings in other cancers [12, 14, 21] . Of note, the origin of MMendothelial cells is actually unknown [42, 43] . The present study supports the idea that these cells are malignantly transformed endothelial cells, perhaps partly due to MM-MVs; this idea is highly consistent with the observation that TMVs can form niches that favor tumor development [22, 44] . It is well known that MVs are important for the intercellular exchange of molecular information [9, 17-19, 29, 45-47] . While the antigens on the surface of MVs can resemble those of their parental cells [48] , many studies have shown that MVs contain a more unique cargo than the parental cells [8, 10, 11, 17, 49] . The microparticles shed from drug-resistant cancer cells are able to spread the cell surface P-glycoprotein (P-gp) to the drug-sensitive recipient cells [11] , and cancer cells harboring oncogenic EGFR can export this receptor in MVs, leading to transformation-like changes in the adjacent tumor cells and endothelial cells [9] . Importantly, secreted miRNAs can be packaged into MVs and delivered into the recipient cells; these miRNAs can then act as physiologically functional molecules to exert gene silencing through the same mechanism as endogenous miRNAs [16] . In the present study, the biologically active molecules horizontally transferred to endothelial cells via MM-MVs may include more than sydecan-1 (CD138), and further studies are needed to explore their contents. Angiogenic cytokines, such as VEGF, have been discovered in exosomes from myeloma cells [21] . It is reasonable to believe that the enriched clusters of molecules in the MM-MVs, as a whole, may possess the ability to transform the target endothelial cells.
Collectively, our data showed that myeloma RPMI 8226 cells can secrete MM-MVs harboring oncogenic CD138, which is a distinct type of angiogenic regulator, and the incorporation of the MM-MVs into endothelial cells lead to the reprogramming of the endothelial cells. We postulate that these events could contribute to the understanding of the complex pathogenesis and progression of myeloma and the distinct nature of the MM-endothelial cells and may help provide new therapeutic targets to treat MM. Because the origins of MVs in patients are highly heterogeneous and are hard to define or study, we chose the RPMI 8226 cell line as the myeloma cell model. The deficiencies are obvious, and further clinical investigations are urgently needed. 
